The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 5, 2002, Pages 908-912

  Tang, Zhao Hui ^a   Qiu, Wen Hong ^a   Wu, Gao Song ^a   Yang, Xiang Ping ^a   Zou, Sheng Quan ^a   Qui, Fa Zu ^a  

^a Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; DENDRITIC CELL VACCINE; DIMETHYLBENZ[A]ANTHRACENE; GAMMA INTERFERON; INTERLEUKIN 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL LYSATE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG PULSE THERAPY; DRUG SPECIFICITY; GENETIC CODE; GENETIC RECOMBINATION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; VACCINATION;

EID: 0036791643     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i5.908     Document Type: Article

References (51)

1. Fuyahiko M, Makoto S, Lianghao D, Peron JM, Cai Q, Robbins PD, Lotze MT. Effective gene therpay for pancreatic cancer by cytokines mediated by restricted replication competent adenovirus. Hum Gene Ther 2000; 11: 223-235
2. Zhou ZH, Song MZ. Current therapies of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2000; 8: 214-15
3. Liu JW, Li KZ. Pancreatic cancer, oncogene and anti oncogene. Shijie Huaren Xiaohua Zazhi 2001; 9: 72-73
4. Zhang SN, Yuan SZ. Gene therapy for pancreatic carcinoma. Shijie Huaren Xiaohua Zazhi 1999; 7: 269-270
5. Liu MP, Zhou JC, Guo XZ, Chen W, Dai B, An TY, Ma SY. Purification and characterization of antigen SC6 for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 1999; 7: 593-595
6. Leng JJ, Chen YQ, Leng XS. Genetic therapy for pancreatic neoplasms. Shijie Huaren Xiaohua Zazhi 2000; 8: 916-918
7. Jia L, Yuan SZ. Progress of treatment of advanced pancreatic carcinoma with gemcitabine. Shijie Huaren Xiaohua Zazhi 1999; 7: 985-986
8. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr. Intranodal Immunization with Tumor Lysatepulsed Dendritic Cells Enhances Protective Antitumor Immunity. Cancer Res 2001; 61: 641-646
9. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein. Cancer Res 2001; 61: 2618-2624
10. Li MS, Yuan AL, Zhang WD. Low immune function of peripheral blood dendritic cells in hepatocarcinoma patients. Shijie Huaren Xiaohua Zazhi 1998; 6: 240-241
11. Li MS, Yuan AL, Zhang WD, Liu SD, Lu AM, Zhou DY. Dendritic cells in vitro induce efficient and special ati-tumor immune response. Shijie Huaren Xiaohua Zazhi 1999; 7: 161-163
12. Chen HB, Zhang JK, Huang ZL, Sun JL, Zhou YQ. Effects of cytokines on dendritic cells against human hepatoma cell line. Shijie Huaren Xiaohua Zazhi 1999; 7: 191-193
13. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells. Lancet 2000; 326: 1163-1165
14. Okamura H, Tsutusui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Namba M, Kurimoto M. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378: 88-91
15. Okamura H, Tsutsui H, Kashiwamura SI, Hakura A, Tanimoto T, Torigoe K, Okura T. IL-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281-288
16. WU HG, Zhou LB, Pan YY, Huang C, Chen HP, Shi Z, Hua XG. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. World J Gastroenterol 1999; 5: 515-517
17. Akita K, Ushio S, Ohtsuki T, Tustsui H, Adarki O, Yoshida N, Tanabe F. Comprison between the biological and biochemical aspects of IL-18 (IFN-gamma-inducing factor) and IL-1β. Proc Am Assoc Cancer Res 1997; 38: 357-362
18. Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol 2001; 75: 8424-8433
19. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, Eisele S, Encke J, Blum HE, Geissler M. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000; 119: 1104-1112
20. Golab J. Interleukin 18-interferon gamma inducing factor - a novel player in tumour immunotherapy? Cytokine 2000; 12: 332-338
21. Qin RY, Ai DI, Zou SQ, Qiu FZ. Development of a new rat model of pancreatic cancer. Zhonghua Shiyian Waike Zazhi 2000; 17: 462-463
22. Kirk CJ, Hartigan D, Nickoloff BJ, Bonini C, Lee SP, Riddell SR, Greenberg PD. T Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine. Augmentation of Dendritic Cell-based Immunotherapy. Cancer Res 2001; 61: 2062-2070
23. Zhang JK, Chen HB, Sun JL, Zhou YQ. Effect of dendritic cells on LPAK cells induced at different times in killing hepatoma cells. Shijie Huaren Xiaohua Zazhi 1999; 7: 673-675
24. Li MS, Yuan AL, Zhang WD, Cheng XQ, Tian XH, Piao YJ. Immune response induced by dendritic cells induce apoptosis and inhibit proliferation of tumor cells. Shijie Huaren Zazhi 2000; 8: 56-58
25. Luo ZB, Luo YH, Lu R, Jin HY, Zhang BP, Xu CP. Immunohistochemical study on dendritic cells in gastric mucosa of patients with gastric cancer and precancerous lesions. Shijie Huaren Xiaohua Zazhi 2000; 8: 400-402
26. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332
27. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I. Identification of HLA-A24 epitope peptides of carcinoembryon antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999; 80: 92-97
28. Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ. Pancreactic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Res 1999; 19: 2471-2475
29. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997; 72: 784-790
30. Thumer B, Haendle I, Roder C, Hubert P, Jacobs N, Giannini SL, Havard L, Renard I, Saboulard D. Vaccination with manage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190; 1669-1678
31. Schnurr M, Galambos P, Scholz C, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. Tumor Cell Lysate-pulsed Human Dendritic Cell Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in vitro Model for Assessment of Tumor Vaccines. Cancer Res 2001; 61: 6445-6450
32. Schnurr M, Galambos P, Scholz C, Fiander A, Man S, Jasani B, Navabi H, Lipez C, Evans AS, Mason M. Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines. Cancer Res 2001; 61: 6445-6450
33. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487
34. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526
35. Jiao, Lo-Man R, Guermonprez P, Fiette L, Deriaud E, Burgaud S, Gicquel B, Winter N, Leclerc C. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 2002; 168: 1294-1301
36. Udewig R, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191: 795-804
37. Holtl L, Rieser C, Papesh C, Gilligan MG, Knox PG, Searle PF. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma afrer vaccination with antigen pulsed dendritic cells. J Urol 1999; 161: 777-782
38. Li J, Holmes LM, Franke KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunothe 2001; 50: 456-462
39. Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K, Chang AE. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 2001; 24: 493-501
40. Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, Reimann J. Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol 2002; 168: 108-117
41. Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213: 4-13
42. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94: 459-473
43. Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 2002; 76: 19-31
44. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fuseed with nonimmunogenic tumor antigens [J]. J Immunol 2001; 167: 6644-6653
45. Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 2000; 7: 83-90
46. Heuer JG, Tucker-McClung C, Hock RA, Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. J Immunother 1999, 22: 324-335
47. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-1749
48. Zitvogel, Mayordomo JI, Tjandrawan T, Gilmore RD Jr, Dolan M, Piesman J, Titus RG. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97
49. Kohyama M, Saijyo K, Hayasida M, Yasugi T, Kurimoto M, Ohno T. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Jpn J Cancer Res 1998; 89: 1041-1046
50. Hirao M, Onai N, Hiroishi K, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson RL. Chemokine receptor-7 on dendritic cells is incuced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 2209-2217
51. Fumiaki T, Wataru H, Haruki O, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K. Rapid generation of potent and tumor specific CTL by interleukin 18 using dendritic cells and naturall killer cells. Cancer Res 2000; 60: 4838-4844